Shots:

• The NMPA has approved Sulinno for the treatment of RA- AS- and psoriasis in China. The approval of the Sulinno marks the expansion of Innovent's portfolio in the non-oncology field
• Sulinno has similar clinical efficacy and safety to its reference product- Humira. The launch will provide Chinese patients with affordable adalimumab- bringing hope and opportunities to more patients
• Sulinno is a biosimilar referencing Humira and is the third mAb approved by NMPA following the approval of Tyvyt (sintilimab) and Byvasda (bevacizumab)

­ Ref: PRNewswire | Image:Innovent